Travere Therapeutics, Inc. (TVTX)
48.35
+0.05
(+0.10%)
USD |
NASDAQ |
Nov 20, 11:26
Travere Therapeutics Cash from Operations (Quarterly) : 98.20M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 98.20M |
| June 30, 2026 | 58.07M |
| March 31, 2026 | -40.37M |
| December 31, 2025 | 60.68M |
| September 30, 2025 | 14.32M |
| June 30, 2025 | 4.983M |
| March 31, 2025 | -42.19M |
| December 31, 2024 | -35.72M |
| September 30, 2024 | -42.51M |
| June 30, 2024 | -40.24M |
| March 31, 2024 | -119.00M |
| December 31, 2023 | -70.47M |
| September 30, 2023 | -59.13M |
| June 30, 2023 | -69.30M |
| March 31, 2023 | -81.12M |
| December 31, 2022 | -54.64M |
| September 30, 2022 | -39.52M |
| June 30, 2022 | -36.81M |
| March 31, 2022 | -55.32M |
| December 31, 2021 | -26.88M |
| September 30, 2021 | 32.06M |
| June 30, 2021 | 6.496M |
| March 31, 2021 | -26.47M |
| December 31, 2020 | -13.87M |
| September 30, 2020 | 6.735M |
| Date | Value |
|---|---|
| June 30, 2020 | -6.453M |
| March 31, 2020 | -29.16M |
| December 31, 2019 | -4.492M |
| September 30, 2019 | -14.12M |
| June 30, 2019 | -19.11M |
| March 31, 2019 | -20.49M |
| December 31, 2018 | -3.565M |
| September 30, 2018 | -3.899M |
| June 30, 2018 | -2.76M |
| March 31, 2018 | -14.73M |
| December 31, 2017 | -0.854M |
| September 30, 2017 | 6.198M |
| June 30, 2017 | 4.835M |
| March 31, 2017 | -2.776M |
| December 31, 2016 | -6.763M |
| September 30, 2016 | 4.744M |
| June 30, 2016 | 3.99M |
| March 31, 2016 | -3.567M |
| December 31, 2015 | -2.549M |
| September 30, 2015 | 1.429M |
| June 30, 2015 | 7.899M |
| March 31, 2015 | -7.333M |
| December 31, 2014 | -9.094M |
| September 30, 2014 | -15.50M |
| June 30, 2014 | -11.45M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 643.10M |
| TG Therapeutics, Inc. | 45.23M |
| Viridian Therapeutics, Inc. | -92.77M |
| Arrowhead Pharmaceuticals, Inc. | -192.40M |
| BioMarin Pharmaceutical, Inc. | 188.21M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -119.63M |
| Cash from Financing (Quarterly) | 27.29M |
| Free Cash Flow | 85.72M |
| Free Cash Flow Per Share (Quarterly) | 0.734 |
| Free Cash Flow to Equity (Quarterly) | 70.20M |
| Free Cash Flow to Firm (Quarterly) | 71.41M |
| Free Cash Flow Yield | 1.85% |